BELLUSCURA PLC LS -01

F:9VQ Germany Medical Devices
Market Cap
$3.30 Million
€3.21 Million EUR
Market Cap Rank
#36141 Global
#4389 in Germany
Share Price
€0.01
Change (1 day)
+0.00%
52-Week Range
€0.01 - €0.02
All Time High
€1.66
About

Belluscura plc develops and commercialize oxygen related medical device products in the United States. The company offers X-PLOR and DISCOV-R, a modular portable oxygen concentrator; and related accessories. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.

BELLUSCURA PLC LS -01 (9VQ) - Net Assets

Latest net assets as of : €- EUR

Based on the latest financial reports, BELLUSCURA PLC LS -01 (9VQ) has net assets worth €- EUR as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

BELLUSCURA PLC LS -01 - Net Assets Trend (None–None)

This chart illustrates how BELLUSCURA PLC LS -01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for BELLUSCURA PLC LS -01 (None–None)

The table below shows the annual net assets of BELLUSCURA PLC LS -01 from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to BELLUSCURA PLC LS -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

BELLUSCURA PLC LS -01 Competitors by Market Cap

The table below lists competitors of BELLUSCURA PLC LS -01 ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BELLUSCURA PLC LS -01's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares BELLUSCURA PLC LS -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently BELLUSCURA PLC LS -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares BELLUSCURA PLC LS -01's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $253,026,393
  • Average return on equity (ROE) among peers: -74.55%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
BELLUSCURA PLC LS -01 (9VQ) €- N/A N/A $966.40K
HeraMED Limited (1I4) $-105.98K 0.00% 0.00x $17.10 Million
Q-linea AB (publ) (3F80) $163.19 Million -164.65% 0.41x $9.23 Million
Guerbet SA (4G8) $342.14 Million 13.51% 1.79x $44.77 Million
Scandinavian Real Heart AB (Publ) (7820) $111.29 Million -9.42% 0.06x $4.77 Million
aap Implantate AG (AAQ1) $54.78 Million 26.71% 0.17x $9.65 Million
Carmat SA (CXT) $7.48 Million -557.76% 3.92x $1.62 Million
elexxion AG (E8X) $-0.01 0.00% 0.00x $199.10K
AETHLON MEDIC.NEW DL-001 (EJU) $15.06 Million -79.86% 0.16x $446.12K
Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) $139.44 Million 15.79% 0.97x $610.05 Million
Gaush Meditech Ltd (F7Y) $1.70 Billion 10.23% 0.68x $29.55 Million